Study to Evaluate Safety and Efficacy of Revanesse® Ultra + vs Revanesse® Ultra for Correction of NLF

NCT02991040 | Completed Results DMC FDA Device

• 1 other identifier: SYM2016-02
• Study Type: interventional
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

A Multicenter, Double-Blind, Randomized, Split-Face Study to Evaluate the Safety and Efficacy of Revanesse® Ultra + (with Lidocaine) versus Revanesse® Ultra for the Correction of Nasolabial Folds to compare the safety and efficacy profiles of Revanesse® Ultra + (with lidocaine, hereafter referred to as Revanesse Ultra +) to Revanesse Ultra for subjects undergoing correction of nasolabial folds (NLFs)

Conditions

Nasolabial Fold Correction

Outcome Measures

Primary Outcomes (1)

• Pain at Injection as Measured by Subject on a 100 mm Visual Analog Scale (VAS) Scale at Time 0 Minutes Post Injection

  Visual Analog Scale for Pain. A 100 mm scale with 0 mm being no pain (best outcome) to 100 mm being worst pain (worst outcome). The higher scores mean a worse outcome

  at injection Time 0

Secondary Outcomes (4)

• Pain Measured by Subject on 100 mm VAS Scale at 15, 30, 45, and 60 Minutes Post Injection and at 2 Weeks Post Injection

  15, 30, 45, and 60 minutes post injection and at 2 weeks post injection

• Wrinkle Severity Rating Score (WSRS)

  Visit 2/Day 14 (± 2 days), Visit 3/Day 28 (± 2 days), Visit 4/Day 84 (± 4 days), Visit 5/Day 168 (Week 24) (± 7 days)

• Patient Global Aesthetic Improvement

  Visit 2/Day 14 (± 2 days), Visit 3/Day 28 (± 2 days), Visit 4/Day 84 (± 4 days), Visit 5/Day 168 (Week 24) (± 7 days)

• Investigator Global Aesthetic Improvement

  Visit 2/Day 14 (± 2 days), Visit 3/Day 28 (± 2 days), Visit 4/Day 84 (± 4 days), Visit 5/Day 168 (Week 24) (± 7 days)

Other Outcomes (1)

• Safety and Tolerability of Revanesse Ultra and Revanesse Ultra+ Injection by Incidence of Treatment Emergent Adverse Events

  at injection, Visit 2/Day 14 (± 2 days), Visit 3/Day 28 (± 2 days), Visit 4/Day 84 (± 4 days), Visit 5/Day 168 (Week 24) (± 7 days)

Study Arms (1)

Revanesse Ultra+

EXPERIMENTAL

Revanesse Ultra+ (with lidocaine) vs Revanesse Ultra without lidocaine

Device: Revanesse Ultra+ (with lidocaine); Device: Revanesse Ultra

Interventions

Revanesse Ultra+ (with lidocaine) DEVICE

Bilateral nasolabial fold trial to compare the safety and efficacy profiles of Revanesse® Ultra + (with lidocaine) to Revanesse® Ultra (comparator)

Also known as: Revanesse Versa+

Revanesse Ultra+

Revanesse Ultra DEVICE

Comparator without lidocaine

Also known as: Revanesse Versa

Revanesse Ultra+

Eligibility Criteria

• Age: 22 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects must meet all of the following criteria to be eligible for the study:
• Men or women 22 years of age or older seeking augmentation therapy for correction of bilateral nasolabial folds.
• Two fully visible bilateral nasolabial folds each with a Wrinkle Severity Rating Scale Score (WSRS) of 3 or 4 that may be corrected with an injectable dermal filler. The NLFs should be symmetrical, i.e., WSRS scores at NLFs on both sides should be the same (both Moderate \[3\] or both Severe \[4\]).
• If female and of childbearing potential, a negative urine pregnancy test and agree to use adequate contraception. Female subjects of childbearing potential (excluding women who are surgically sterilized or postmenopausal for at least 2 years) must have a negative urine pregnancy test and must be willing to use a medically accepted method of contraception during the study. The following are considered acceptable methods of birth control for the purpose of this study: oral contraceptives, contraceptive patches, contraceptive implant, vaginal contraceptive, double barrier methods (e.g., condom and spermicide), contraceptive injection (Depo-Provera®), intrauterine device (IUD), hormonal IUD (Mirena®), and abstinence with a documented second acceptable method of birth control if the subject becomes sexually active. Subjects entering the study who are on hormonal contraceptives must have been on the method for at least 90 days prior to the study and continue the method for the duration of the study. Subjects who had used hormonal contraception and stopped must have stopped no less than 90 days prior to Visit 1/Day 1.
• Ability to understand and comply with the requirements of the study.
• Willingness and ability to provide written informed consent. 6. Agree to refrain from seeking other treatment for this condition during the study.

You may not qualify if:

• Subjects who meet any of the following criteria will be excluded from the study:
• Wrinkle Severity Rating Scale Score of ≤ 2 on the right or left nasolabial fold.
• Women who are pregnant or lactating.
• Received prior dermabrasion, facelift, or Botox below the orbital rim, or had undergone procedures based on active dermal response (e.g., laser or chemical peeling procedures) within 6 months (180 days) prior to study entry.
• Use of any facial tissue augmenting therapy with non-permanent filler or aesthetic facial surgical therapy within 9 months prior to study entry.
• Has ever received semi-permanent fillers anywhere in the face or neck, or is planning to be implanted with these products during the study.
• Has a permanent implant placed in the NLF area.
• Evidence of scar-related disease or delayed healing activity within the past 1 year.
• Scars at the intended treatment sites.
• History of keloid formation or hypertrophic scars.
• Any infection or unhealed wound on the face.
• Allergic history including anaphylaxis, multiple severe allergies, atopy, or allergies to natural rubber latex, lidocaine or any amide-based anesthetic, hyaluronic acid products, or Streptococcal proteins or have plans to undergo desensitization therapy during the term of the study.
• Aspirin or nonsteroidal anti-inflammatory drugs within 1 week (7 days) prior to treatment.
• Concomitant anticoagulant therapy, antiplatelet therapy, or history of bleeding disorders, coagulation defects or connective tissue disorders.
• Over-the-counter (OTC) wrinkle products or prescription wrinkle treatments within 4 weeks (28 days) prior to treatment and throughout the study.

Sponsors & Collaborators

• Prollenium Medical Technologies Inc.: lead

Study Sites (1)

Tennessee Clinical Research Center

Nashville, Tennessee, 37215, United States

Location

Results Point of Contact

• Title: Mr. Ario Khoshbin
• Organization: Prollenium Medical Technologies Inc.

ario@prollenium.com

+1 (905) 508-1469

Study Officials

• Michael H. Gold, MD

  Tennessee Clinical Research, Inc

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Masking Details: The side of the face for each product was randomly assigned. The investigator performing the evaluations and the subject were blinded to the treatment; injections of the study product were performed by an unblinded injecting investigator.
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Subjects were treated with Revanesse Ultra in the NLF on one side of the face and Revanesse Ultra+ in the NLF on the other side of the face. The side of the face for each study product was randomly assigned.

Study Record Dates

• First Submitted: December 6, 2016
• First Posted: December 13, 2016
• Study Start: August 1, 2016
• Primary Completion: August 1, 2017
• Study Completion: August 1, 2017
• Last Updated: April 11, 2019
• Results First Posted: April 11, 2019

Record last verified: 2019-03

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)